Major Funding Milestone
Conceivable Life Sciences, a pioneering biotech firm dedicated to transforming fertility care, has successfully closed an $18 million Series A financing round. This significant funding was led by ARTIS Ventures, with additional investments from Atlantic Health Venture Studio, Muse Capital, and Scrub Capital. Existing investors such as ACME Capital, Black Opal Ventures, and Cadence Healthcare Ventures also contributed, bringing the company’s total funding to over $39 million. Conceivable aims to utilize this capital to advance its AI-powered automated IVF lab, setting a new benchmark in fertility treatment.
Breakthrough in Fertility Technology
Conceivable’s innovative approach integrates AI and robotics to automate the complex process of in vitro fertilization (IVF). The company has notably achieved the first fully automated intracytoplasmic sperm injection (ICSI), performed both onsite and remotely, with operations spanning 3,000 miles between reproductive cells and an embryologist in New York. This groundbreaking achievement was highlighted during a mainstage presentation at the 2024 European Society of Human Reproduction and Embryology (ESHRE). Dr. Alejandro Chavez-Badiola, the company’s co-founder and Chief Product Officer, emphasized the need for automation in IVF labs, which have remained largely manual despite advancements in other medical fields. Conceivable’s interdisciplinary team is working to modernize these labs, aiming for improved clinical outcomes and broader access to fertility care.
Future Plans and Market Impact
The newly acquired funding will support a commercial pilot, including a 100-patient Institutional Review Board (IRB) study currently in progress. Preliminary results from a previous IRB study showed promising outcomes, with 22 pregnancies achieved after the first embryo transfer using Conceivable’s first-generation AI platform. The company is preparing for a U.S. launch targeted for early 2026. Alan Murray, co-founder and CEO, expressed pride in the company’s progress and the robust scientific foundation they’ve established.
The investment underscores the transformative potential of Conceivable’s technology, which aims to democratize IVF by reducing costs and increasing accessibility. Stuart Peterson, Managing Partner at ARTIS Ventures, highlighted the significant unmet demand for IVF, noting that Conceivable Life Sciences’s scalable solution could provide equitable fertility care globally. With the high costs of current IVF treatments, Conceivable’s innovations promise to make starting a family a reality for many more individuals.
